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Bioreductive fluorescent imaging agents:
applications to tumour hypoxia
Robert B. P. Elmes
Large tumours contain regions with very low intracellular O2 concentrations. Known as hypoxia, this
feature of tumours yields a highly reducing environment owing to the presence of numerous oxygen
sensitive reductase enzymes. The development of new optical chemosensors for these various
reductases presents an ideal approach to visualise areas of hypoxia or highly reducing environments.
Critical to the success of such chemosensors is the design of probes containing a bioreductively
activated moiety that either ensures the selective retention of fluorescence within a hypoxic tissue or a
probe that irreversibly releases a reporter fluorophore. This Feature Article aims to summarise the
fluorescent tools that have been developed to image tumour hypoxia and the various reductase
enzymes associated with the bioreduction process.
1. Introduction
Hypoxia, a diminished availability of molecular oxygen in bodily
tissues, has long been a therapeutic target for cancer research
given its major role in tumour development and resistance to
therapy.1,2 The imperfect neovascularisation seen in growing
solid tumours results in limited and inefficient blood vessel
networks, and leads to the presence of a variable but significant
proportion of hypoxic cells.3 Indeed, since the discovery of
Varghese et al. in 1976 that 2-nitroimidazoles are capable of
forming adducts with cellular nucleophiles in hypoxic cells,4
hypoxia-activated prodrugs have been the subject of intense
investigation culminating with the recent entry of evofosfamide
(Fig. 1) into stage 3 clinical trials for pancreatic cancer and soft
tissue sarcoma.5–7
The proposed activation of 2-nitroimidazoles stems from an
initial enzymatic bioreduction resulting in the delivery of an
electron to the nitro group yielding a nitro radical. Under
aerobic conditions, the nitro radical is back-oxidised to the
parent nitro compound by molecular oxygen which is converted
to a superoxide anion and subsequently transformed to hydrogen
peroxide by superoxide dismutase (SOD).8 However, in hypoxic
regions oxygen pressures can fall to below 2.5 mmHg,9 inhibiting
the back-oxidation of the nitro radical anion and prompting
further reduction to nitroso and subsequently hydroxylamine
and amine derivatives. This ‘unmasking’ yields ideal substrates
for covalent attachment to intracellular nucleophiles (i.e. proteins
or DNA) and selective retention in hypoxic cells relative to
normoxic cells (Fig. 1a). This reduction process is also exploited
by prodrugs such as evofosfamide to trigger release of the active
drug molecule (Fig. 1b).
In mammalian cells, a number of different reductase enzymes
associated with the cytoplasm, mitochondria, and microsomes
have been implicated in the bioreduction of 2-nitroimidazoles. These
include one-electron reductases such as NADPH–nitroreductases,
NADPH–cytochrome P450 reductase, cytochrome b5 reductase
and xanthine oxidase, and two-electron reductases such as
DT-diaphorase.10 Moreover, a host of other functionalities such
4-nitroimidazoles, 4-nitrobenzenes, nitrofurans, azo linkages,
tertiary amine N-oxides, aromatic di-N-oxides and quinones
have all been shown to be susceptible to reduction by the
various reductase enzymes.9 In essence, the observed diversity
of both enzymes and substrates provides an assortment of tools
available not only for the design of hypoxia targeting agents but
also to selectively target tissues in which the aforementioned
enzymes reside. Indeed, the inextricably linked role of reductase
enzymes with hypoxia has boosted research into the development
of techniques to accurately detect and profile their function.
To date many detection techniques such as 19F NMR, positron
emission tomography (PET), single-photon emission computed
tomography (SPECT) and immunohistochemistry to name just
a few have exploited bioreducible agents.11
The bioreduction approach is also particularly amenable to
fluorescence detection. Fluorescence signals have been extensively
exploited as analytical tools to monitor many biological processes
both in vitro and in vivo.12,13 Techniques such as confocal micro-
scopy imaging, benefit from high spatial and temporal resolutions
where the selective sensing of the desired enzyme enables facile
intracellular monitoring and provides valuable information
on biological role and functions. Moreover, the potential for
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‘turn on’ fluorescent probes brings with it incomparable levels of
sensitivity and selectivity and has led to a burgeoning interest in
reductively activated fluorescent imaging agents.14
This Feature Article aims to be a non-exhaustive summary of
the fluorescent tools that have been developed to detect tumour
hypoxia and the various reductase enzymes associated with the
bioreduction process. It will focus on chemical probes whereby a
reduction leads to the release of a fluorescent reporter molecule
but also fluorescent probes that are selectively retained in cancer-
ous tissue for imaging applications. The review will not cover
oxygen sensing probes or redox active transition metal complexes
which have been reviewed elsewhere.15,16 The bioactivatable
probes presented herein exploit various functionalities such as
nitroaromatics, azo linkages, quinolones and N-oxides among
others. It will highlight early attempts to exploit non-fluorogenic
nitroaryl substrates up to more recent exploitation of FRET-
based azo conjugates. The recent application of similar tools
for probing bacterial activity through reductase enzymes will also
be described along with some innovative cascade type reactions
resulting from bioreduction.
2. Nitroaromatics
The majority of the examples described in this review rely on
the reduction of a nitroaromatic moiety present in the structure
of a fluorophore. This interest stems from the electron affinity
of the nitro functional group and it’s ease of reduction by nitro-
reductase (NTR) enzymes.17 These flavin-associated oxidoreductase
enzymes can be divided into two functional classes. Type I NTRs
are oxygen-insensitive, i.e. capable of reduction in the presence
of molecular oxygen, whereas type II NTRs are oxygen-sensitive
and only function under extreme hypoxia.18 Owing to their role
in hypoxia type II NTRs are of particular significance to the
design of hypoxia sensitive fluorescent imaging agents.
The early work of Olive and Durand recognised the utility of
nitroaromatics for hypoxia imaging where they reported a small
family of nitrofurans 1–4 (Fig. 2).19 They demonstrated that, 1
could be used to estimate the fraction of hypoxic cells in multi-
cellular spheroids where they discovered that the fluorescence
intensity of 1was highly responsive to cellular oxygen concentration.
These results presented one of the first studies on the feasibility of
nitroheterocycles as hypoxia sensors and several reports followed
on the potential applicability of nitrofurans as fluorescent hypoxic
cell markers.20–22
Further pioneering work was conducted by Hodgkiss,
Middleton, Stratford, Wardman and co-workers who published
a number of reports on the use of nitroaryl compounds as
potential fluorescent probes for hypoxia. After a preliminary
screening of a series of compounds with similar structure,23
their initial investigations focused on the use of nitroakridin
3582,24 (5) and 3-nitronaphthalimide25,26 (6) (Fig. 3) which were
shown to be non-fluorescent until reduction of their nitro
groups to the corresponding amines resulted in intense fluores-
cence at 515 nm and 570 nm respectively. They showed, using
flow cytometry and HPLC analysis, that both 5 and 6 became
highly fluorescent under hypoxic conditions in a number of cell
lines but not in the corresponding normoxic cells.27 However,
in vivo investigations showed that tumours did not appear to
accumulate 5 to any great extent, with levels of o10 mM being
Fig. 1 (a) The proposed oxygen-dependent bioreductive metabolism of 2-Nitroimidazoles and mechanism for selective retention in hypoxic cells.
(b) 2-Nitroimidazole containing bioreductive prodrug evofosfamide is activated under hypoxic conditions where reduction leads to fragmentation of
the parent drug to release an active DNA crosslinking agent.
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observed in the tumours of a male mouse model compared
to concentrations of 600 mm being observed in the liver.26
This large degree of liver accumulation also resulted in signifi-
cant toxicity where the compound was not tolerated at doses
above 0.19 mmol g1.
A subsequent series of reports focused on compounds
having both a 2-nitroimidazole and a fluorescent ring system
in their molecular structure (Fig. 4).28,29 Bioreduction of the
nitroimidazole was expected to lead to compounds that would
exhibit fluorescence in both normoxic and hypoxic cells but,
due to the presence of the reduced nitroimidazole moiety, would be
selectively bound in hypoxic cells and thus the fluorescence would
be ‘fixed’ in these cells. The authors prepared a range of compounds
based on various fluorophores such as naphthalimide 7, coumarin
8, indolizine 9 and bicyclic bimane 10 where 8 and 10 showed
more than a 5-fold and 17-fold hypoxic/normoxic fluorescence
differential, respectively, when tested in V79 Chinese hamster
cells. Hodgkiss later reported an alternative strategy involving
biotinylated 2-nitroimidazoles such as 11.30 Bioreductively
bound adducts of 11 could be clearly detected using either an
avidin or streptavidin–FITC conjugate when analysed by flow
cytometry and could also be observed in tumour cells of mice
which had been exposed to the compound in vivo.
Qian and co-workers have explored a number of strategies
towards fluorescent markers for hypoxia where their first report
focused on 1,8-naphthalimides functionalised with either two
2-nitroimidazole or two 3-nitro-1,2,4-triazole moieties (Fig. 5).14,31
When evaluated in V79 Chinese hamster, CHO and 95D cells the
2-nitroimidazole compounds 12 and 13 showed a large fluorescence
differential between hypoxic and normoxic cells as evidenced by
fluorescence microscopy and fluorescence scanning ascent. Indeed,
compound 13 showed the largest degree of fluorescence differential
with the fluorescence under hypoxic conditions being 20 times
as intense as under normoxic conditions.
Derivatives 14 and 15 (Fig. 5) also showed promise as
fluorescent markers for hypoxia where both compounds were
shown to exhibit increased fluorescence in response to hypoxic
conditions in V79 Chinese hamster cells.32 Similarly to 12 and
13 above, the 2-nitroimidazole compound 15 containing an ether
linkage exhibited the largest fluorescence differential where
bioreduced 15 exhibited 15 times increased emission compared
to it’s non reduced nitro analogue.
Qian and co-workers also investigated two series of hypoxia
sensors that lacked the 2-nitroimidazole group (Fig. 6).
Fig. 3 Nitroaryl compounds 5 and 6.
Fig. 2 Nitrofuran derivatives 1–4.
Fig. 4 2-Nitroimidazole conjugates 7–11.
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This alternative approach was based on either a 7H-benzimid-
azole[2,1-a]benz[de]isoquinolin-7-one core such as 16 and 17 or
on an acenaphtho[1,2-b]quinoxaline core such as 18, 19 and 20.
Compounds 16 and 17 showed particular promise with 16
showing a normoxic/hypoxic fluorescence ratio of 14 when tested
in V79 Chinese hamster cells.33 A similar approach was taken
with 18, 19 and 20, based on the principle of a quenching nitro-
group being reduced under hypoxic conditions. This resulted in
hypoxic/normoxic fluorescence differentials of 6, 9, and 11 times
with 18, 19, and 20 respectively when incubated for 3.5 h in V79
Chinese hamster cells.34
The recent development of a ratiometric fluorescent probe
for hypoxia saw the synthesis of naphthalimide probe 21, based
on a p-nitrobenzyl moiety being conjugated to the naphthalimide
fluorophore via a carbamate linkage.35 Using a prodrug approach
analogous to that utilised by evofosfamide, this highly selective
ratiometric fluorescent sensor was shown to be activated by NTR
in the presence of NADH with an obvious blue to green fluores-
cence shift resulting from release of 4-amino naphthalimide
derivative 21a (Fig. 7). A similar response was observed in vitro
when the probe was incubated in A549 cells cultured under
hypoxic conditions. Moreover, 21 displayed no cytotoxicity thus
rendering it a promising candidate as a potential biological
imaging agent for hypoxia (Fig. 8).
A similar approach was utilised in the development of 22, a
Nile Blue based long-wavelength fluorescence probe for the
detection of NTR which was activated at concentrations as low
as 0.1 mM to release the highly fluorescent dye 23.36 22 was
found to be both highly sensitive and selective where the
detection limit was determined to be 180 ng mL1 of NTR
while also being stable towards other biological reductants such
as dithiothreitol (DTT), glutathione (GSH), cysteine (Cys) and
homocysteine (Hcy) with minimal endogenous interference.
Moreover, 22 did not exhibit any cytotoxicity and A549 cells
incubated under hypoxic conditions showed a large fluores-
cence enhancement (Fig. 9).
Nakata, Hori and co-workers designed 24; a fluorescent pH
probe selectively activated under hypoxic conditions.37 24 consists
of a p-nitrobenzyl moiety directly linked to the commercially
available xanthene derivative seminaphthorhodafluor (SNARF)
Fig. 5 2-Nitroimidazole–naphthalimide derivatives 12–15.
Fig. 6 Nitroaromatic compounds 16–20.
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Fig. 7 Conversion of fluorescent sensor 21 to 4-amino-naphthalimide 21a.
Fig. 8 Fluorescence microphotographs of A549 cells incubated with 21 under normoxic (a–c) and hypoxic (d–f) conditions. (Reproduced with
permission from Org. Lett., 2011, 13, 928–931. r 2011 American Chemical Society).
Fig. 9 The conversion of 22 to 23 in the presence of NTR and NADH. (a) Fluorescence microphotographs of A549 cells incubated with 22 under various
normoxic and hypoxic conditions. (b) Mean fluorescence intensity change of A549 cells incubated with 22 under various normoxic and hypoxic
conditions. (Reproduced from Chem. Commun., 2013, 49, 10820–10822. r 2013 Royal Society of Chemistry).
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through an ether linkage. Reduction of the p-nitrobenzyl moiety
by either NTR or chicken embryo liver microsomes under hypoxic
conditions led to the release of SNARF which was capable of acting
as a fluorescent pH indicator (Fig. 10). Moreover, fluorescent
imaging of V79 Chinese hamster cells revealed that 24was strongly
fluorescent in the cytosol of cells incubated under hypoxic condi-
tions while negligible fluorescence was observed in the cells
treated under aerobic conditions.
Jayagopal and co-workers developed two hypoxia-sensitive
imaging agents, 25 and 26, based on 2-nitroimidazole fluorescein
isothiocyanate (FITC) conjugates (Fig. 11).38 26 in particular was
shown to be effective in human Mu¨ller cells at low concentration
(10 mM) where a 32-fold greater fluorescence intensity was
measured in hypoxic cells when compared against normoxic
cells; a demonstration of its ability to be selectively retained in
hypoxic retinal cells. Furthermore, intraocular administration
Fig. 10 (a) Bioreduction of 24 to releases the pH responsive fluorophore SNARF. (b) The fluorescence spectra of 24 in the presence (black) or absence
(red) of NTR at pH 5.0 (dot line), pH 7.0 (solid line) and pH 9.0 (dashed line). Inset: Photograph of the ratiometric fluorescent response to different
pH conditions with or without NTR. (Reproduced with permission from Bioorg. Med. Chem., 2009, 17, 6952–6958. r 2009 Elsevier).
Fig. 11 2-Nitroimidazole fluorescein isothiocyanate conjugates 25 and 26.
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of 25 and 26 in mouse models of retinal hypoxia enabled ex vivo
imaging of dissected retinae where accumulation of intravitre-
ally injected 25 and 26 in hypoxic areas were clearly observed.
These results demonstrated the clear utility of these probes for
studying the role of hypoxia in retinal diseases in addition to
other tissues featuring hypoxic regions.
Paulmurugan and co-workers demonstrated the utility of
CytoCy5Sr27 to track NTR-mediated gene expression both in vitro
and in vivo (Fig. 12).39 27 is a quenched substrate of NTR owing to
the presence of two nitro substituents, however, upon reduction by
cellular NTR 27 became intensely fluorescent at 638 nm. The authors
demonstrated the utility of such an approachwhere they successfully
monitored NTR gene expression in NTR transfected cells and also in
NTR positive tumour xenografts in live nudemice using fluorescence
imaging. Gjertsen and co-workers developed a squaraine analogue
28 for similar applications where their methodology allowed evalua-
tion of NTR gene directed enzyme prodrug therapy (GDEPT) with
a well-known antibiotic metronidazole without interference of the
therapeutic potential (Fig. 12).40 This approach perfectly exemplified
the broad potential clinical applications for this approach in terms
of both imaging and gene therapy.
Nagasawa and co-workers developed two 2-nitroimidazole-
tricarbocyanine conjugates 29 and 30 (Fig. 13).41,42 Unlike
previous examples that displayed a fluorescence ‘switching on’
effect, both 29 and 30 displayed fluorescence quantum yields of
0.18 and 0.05 respectively in their quiescent state. However,
upon bioreductive activation of the 2-nitroimidazole moiety,
selective binding and accumulation of both dyes occurred
preferentially in hypoxic cells over normoxic cells as evidenced
by fluorescence microscopy. In vivo fluorescence imaging also
specifically detected 29 and 30 in subcutaneous tumours of nude
mice inoculated with SUIT-2/HRE-Luc cells. Interestingly, ex vivo
immunohistochemical analysis of the excised tumours also
revealed a strong correlation between 29 and areas expressing
the well-known hypoxia marker hypoxia inducible factor 1a
(HIF 1a) suggesting the potential application of 29 as an in vivo
optical imaging probe.
Smith, Zhu and co-workers have pursued an analogous
approach to hypoxia imaging with a number of reports detailing
their efforts towards imidazole–indocyanine green conjugates
31–35 (Fig. 14). Their first generation fluorophore 31 was shown
to display a large contrast in fluorescence intensity (2.5 fold)
Fig. 12 Cyanine and squaraine based fluorescent sensors 27 and 28.
Fig. 13 2-Nitroimidazole–cyanine conjugates 29 and 30.
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between 4T1 breast cancer cells treated under hypoxic and
normoxic conditions.43 Moreover, when measured in an in vivo
tumour model, 31 was also shown to exhibit two-fold higher
fluorescence at the tumour site when compared against the
untargeted dye 32.44 A subsequent report detailed the synthesis
and evaluation of the more metabolically stable fluorophore 33
where the labile ester linkage was replaced by a more robust
piperazine moiety.45 Fluorescence tomography analysis of mouse
tumours revealed that 33 showed 2-fold higher fluorescence in
hypoxic tumours relative to 31, within three hours post-injection
while it was measured as 1.6–1.7 times higher beyond 3 hours.
A more recent article reported the synthesis and evaluation of a
third generation dye 34 where the polyene linker had been
reduced in length by two carbon atoms.46 With a more planar
and rigid structure, 34 displayed markedly different photo-
physical characteristics showing absorption and emission
maxima of 657 nm and 670 nm respectively; shifted B100 nm
from themaxima of 33 (755 nm and 780 nm respectively). 34 also
displayed a fluorescence quantum yield of 0.467 (5 times higher
than that of 33) which resulted in more than two times the
average in vivo fluorescence intensity being measured for 34 when
compared to 33 in a mouse tumour even though 33 was retained
in the tumour to a greater extent. Utilising the considerably more
cost effective 4-nitroimidazole moiety Smith, Zhu and co-workers
also recently reported the preparation of the 4-nitroimidazole–
piperazine–indocyanine derivative 35.47 The introduction of a
4-nitroimidazole moiety was shown to not significantly affect
the retention of the dye in tumours where, in fact, 35 showed a
1.5-fold higher fluorescent intensity after 15 min post-injection
compared to 33 when measured in BALB/c tumour-bearing
female mice. However, there are some concerns around the toxicity
of 4-nitroimidazole containing compounds48 thus further research
is on-going to determine any toxic effects associated with 35.
Tang and co-workers developed the 2-nitroimidazole tri-
carbocyanine conjugate 36 as a probe for intracellular hypoxia
(Fig. 15).49 Treatment of 36 with rat liver microsomes known to
contain several reductase enzymes produced a strong absorp-
tion peak at 695 nm and concomitant fluorescence emission at
750 nm. Moreover, 36 was found to be highly selective for NTR,
non-toxic and displayed a detection limit of 77 ng mL1. Using
36 as a marker for hypoxia, the authors revealed that under
hypoxia HepG2 cells exhibit down-regulation of E-cadherin
expression with concomitant up-regulation of a smooth muscle
actin (a-SMA) expression; two known markers of the epithelial–
mesenchymal transitions (EMTs) in tumour migration.
Shi et al. used a similar approach where they reported the
synthesis of the p-nitrobenzyl–cyanine derivative 37 (Fig. 15).50
NTR was found to reduce the aromatic nitro group causing
self-immolative fragmentation and resulting in restoration of
p-electron conjugation yielding aB50-fold fluorescence emission
enhancement at 708 nm (Fig. 16). Like 36, 37 was shown to be
highly selective for NTR where other biological reductants such
glutathione, cysteine, homocysteine and dithiothreitol did not
cause any noticeable changes in emission.
Feng, Li and co-workers recently reported an ultrasensitive
method for in vivo NTR imaging based on nitroaryl–cyanine
conjugates 38–42 (Fig. 17).51 Of the compounds synthesised,
only 38 showed appreciable sensitivity to NTR thought to be a
result of enzyme substrate specificity where 39–42 could not
approach the active site of NTR in a favoured spatial arrangement.
Fig. 14 Nitroimidazole–indocyanine green conjugates 31–35.
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In contrast, 38 showed a fluorescence quantum yield ofo0.1%
before bioreduction but in the presence of NTR and NADH
gave rise to a 110-fold fluorescence emission enhancement
in the NIR region (lmax = 782 nm) and a detection limit of
1.14 ng mL1. In vitro imaging of hypoxic A549 cells at various
oxygen concentrations (20%, 10%, 5%, 3% and 1%) demon-
strated the ability of 38 to act as an in cellulo imaging agent for
hypoxia. Furthermore, time course in vivo fluorescence imaging
of an A549 mouse tumour model revealed NIR fluorescence
within 2 seconds of injecting 38 with an 8-fold higher intensity
measured inside the tumour within 3 minutes (Fig. 18).
Sha, Zhang and co-workers recently reported the synthesis of
43 (Fig. 19), an analogous cyanine based ‘turn on’ fluorescent
probe for NTR.52 Taking advantage of a nitrobenzyl trigger, 43
demonstrated a highly sensitive and selective response to
NTR in vitro culminating in an 80-fold fluorescence increase
at 720 nm upon exposure to NTR and NADH. Similarly, 43 was
also capable of imaging HeLa cells under hypoxic conditions
(1% O2) while under normoxic conditions (20% O2) no fluores-
cence was detected.
Jiang and co-workers described the cyanine derived ratio-
metric probe 44 (Fig. 20).53 44 displayed characteristic fluores-
cence emission at 805 nm, however, upon bioreduction in the
presence of NTR and NADH a decrease in fluorescence intensity
at 805 nm was observed with the concomitant appearance of a
blue-shifted emission band at 747 nm. HRMS-ESI analysis
revealed that such changes were a result of bioreduction
of the p-nitrobenzyl moiety followed by a 1,6-elimination/
decarboxylation mechanism releasing dye 45. Moreover, 44
was found to be highly selective and sensitive exhibiting a
calculated detection limit of 0.0058 ng mL1; the lowest detec-
tion limit for NTR reported to date. Cell imaging studies
revealed that 44 was also capable of distinguishing between
hypoxic and normoxic cells by dual-emission ratiometry.
A semi-cyanine fluorophore 46 has also been utilised by
Qian and co-workers for the detection of NTR and hypoxia
(Fig. 21).54 This selective turn-on fluorescent probe is activated
by NTR where reduction of a p-nitrophenyl to a p-aminophenyl
group leads to restoration of the pull–push electronic system of
the semi-cyanine. Such reduction resulted in an 85 fold fluores-
cence emission enhancement at 556 nm with a detection limit
of 40 ng mL1 within 30 minutes. The probe, while exhibiting
little cytotoxicity to A549 cells, was also capable of in vitro
imaging of these cells under hypoxia. A549 cells treated with 46
under normoxic conditions showed no appreciable fluores-
cence, however, at 1% oxygen an increase in red fluorescence
was clearly observed.
Ma and co-workers synthesised a resorufin based fluoro-
phore 47 utilising 5-nitrofuran as a hypoxia sensitive trigger
(Fig. 22).55 47 detected NTR through bioreduction resulting in a
1,6-rearrangement-elimination mechanism that released resor-
ufin giving rise to both colourimetric (colourless to pink) and
fluorescence (non-fluorescent to intense red fluorescence)
modulations. Again, 47 was shown to be both highly selective
and sensitive for NTR (detection limit = 27 ng mL1) and
displayed a non-toxic biological profile. Through it’s sensitivity
for NTR, 47 was used to image A549 and HeLa cells under
different extents of hypoxia using confocal microscopy.
No considerable fluorescence was observed from cells under
normoxia (20% O2) while fluorescence intensity at 585 nm
increased in response to decreasing levels of O2 from 20% to
1%. An analogous approach was used by the same group where
the related 5-nitrothiophene derivative 48 was also shown to act
as an ‘off–on’ fluorescence probe for NTR (Fig. 22).56 48 showed
similar selectivity towards NTR but with higher sensitivity
(detection limit = 0.2 ng mL1) and, interestingly, was capable
of quantitatively determining the concentration of NTR pro-
duced by Escherichia coli in culture; the first such example with
potential for real-time and quantitative determination of NTR
in biological organisms.
Fig. 15 Cyanine derivatives 36 and 37.
Fig. 16 The fluorescence response of 37 to NTR in the presence of
NADH. The insets depict the fluorescence change to the naked eye under
UV irradiation. (Reproduced from Analyst, 2013, 138, 1952–1955. r 2013
Royal Society of Chemistry).
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Ma and co-workers pursued an alternative fluorophore in
their subsequent report which took advantage of a cresyl violet
based probe 49 for the detection of NTR in both MCF-7 cells
and zebrafish (Fig. 23).57 As in previous reports NTR was shown
to catalyse the reduction of a nitroaromatic moiety within the
probe structure resulting in a large fluorescence enhancement
at 625 nm. 49 detected NTR in aqueous solution with high
selectivity and sensitivity (detection limit = 1 ng mL1) and
also displayed intense fluorescence within hypoxic MCF7 cells.
Moreover, cells cultured in 5% and 1% O2 were shown to display
Fig. 17 Nitroaryl–cyanine conjugates 38–42.
Fig. 18 In vivo fluorescence imaging of an A549 tumour model (a) before and (b) after injecting 38. (c) The fluorescence time-course experiment of 38
in solution (black) and upon exposure to the tumour region (red) from 0 to 180 seconds after injection. (Reproduced with permission from J. Am. Chem.
Soc., 2015, 137, 6407–6416. r 2015 American Chemical Society).
Fig. 19 Nitrobenzyl–cyanine conjugate 43.
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1.6 and 3 times stronger fluorescence respectively when com-
pared against normoxic cells; indicating that endogenous NTR
levels increase in response to a decrease in O2 concentration.
Exploratory experiments using 49 also indicated the presence of
endogenous NTR in zebrafish embryos where, interestingly,
fluorescence microscopy suggested a non-uniform distribution
of NTR in this organism. A subsequent report aimed to clarify
this effect with the design and synthesis of 50 (Fig. 23), a new
fluorescent probe with ‘off–on’ properties displaying maximum
fluorescence at 670 nm.58 Similar to Ma’s previous examples 50
displayed exquisite selectivity over other biological interferents,
good sensitivity towards NTR (detection limit = 14 ng mL1)
and good biocompatibility when measured in HeLa cells.
Fluorescence imaging of zebrafish embryos treated with 50
displayed intense and non-uniform fluorescence implying that
50 localises to specific tissues within the zebrafish but also
confirming the findings of their previous report that suggested
the presence of endogenous NTR. Confirmation of this was
attained by treating the same zebrafish with the known NTR
inhibitor dicoumarol which resulted in a significantly weaker
fluorescence signal than that from the untreated animal;
an indication that dicoumarol was effectively inhibiting the
activity of endogenous NTR (Fig. 24).
BODIPY based probe 51, a quaternarised 4-pyridinyl-substituted
fluorophore conjugated to 5-nitrofuran was developed by Shao,
Li and co-workers (Fig. 25).59 Bioreduction of the nitrofuran
moiety by NTR in the presence of NADH was found to release the
4-pyridinyl BODIPY dye 52 resulting in a concomitant 20-fold
increase in fluorescence intensity at 520 nm. Furthermore, 51
was found to be a selective and sensitive probe being stable to
a number of interferants (NaCl, KCl, CaCl2, MgCl2, cysteine,
glutathione, dithiothreitol, glutamic acid, arginine, vitamin C,
vitamin B6, H2O2, HClO, glucose and human serum albumin)
while also displaying a detection limit of 9.6 ng mL1. Being
highly sensitive to NTR 51 was also shown to be amenable to
biological application where it was used to track the quantities
of NTR produced by E. coli in culture and also to act as a
Fig. 20 Cyanine derived probe 44 and reduction product 45.
Fig. 21 Semi-cyanine fluorophore 46.
Fig. 23 Cresyl violet and semi-cyanine based probes 49 and 50.
Fig. 22 Resorufin based fluorophores 47 and 48.
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sensitive fluorescent imaging agent for hypoxic A549 cells
human epithelial lung carcinoma cells. More recently, another
BODIPY based probe 53 has been reported as a ‘turn-on’
fluorescent probe for hypoxic cell imaging (Fig. 25).60 Using
time-dependent density functional theory (TD-DFT) calculations,
the authors discovered that the presence of a nitrohydroxy-phenyl
ring resulted in a nonradiative decay of the S1 excited state of 53
with subsequent reduction of the nitro group leading to a recovery
of fluorescence. This finding was confirmed in a biological context
where HeLa cells treated with 53 under normoxic conditions
showed negligible intracellular fluorescence while cells incubated
with under hypoxic conditions produced significant intracellular
between 550 and 650 nm (Fig. 26).
Recently Debieu and Romieu reported innovative dual enzyme-
responsive sensors 54–56 based on the in situ formation of
7-hydroxy-2-iminocoumarins (Fig. 27).61 The ‘‘AND’’ fluorogenic
molecular logic gate design concept employed allowed simultaneous
fluorogenic detection of hydrolase and reductase enzymes. Double
activation through both hydrolysis of an amide (or ester) bond and
nitro-reduction, followed by a 1,6-elimination/cyclisation gave
fluorescence at 489 nm caused by release of 7-hydroxy-(2-imino)-
coumarin species. The coumarin fluorophore was also exploited by
Mishra and co-workers who reported the synthesis of two coumarin–
nitroimidazole conjugates 57 and 58 (Fig. 27).62 57 in particular
was shown to be selectively retained in hypoxic cells exhibiting
a 10 fold fluorescence increase in flow cytometry experiments
with a negligible signal being observed in normoxic cells.
Jiang, Tan and co-workers reported the nitro-substituted
benzothiadiazole probe 59 capable of labelling hypoxic cells with
‘switched on’ fluorescence at 600 nm in response to bioreduction
(Fig. 28).63 59 showed no cytotoxicity to human osteosarcoma
MG63 cells and effectively labelled 65% of cells grown under
hypoxic conditions in comparison to only 2.4% under normoxic
conditions as evidenced by flow cytometry analysis.
In an unexpected revelation Gates and co-workers reported the
hypoxia selective enzymatic conversion of 6-nitroquinoline 60
into the fluorescent helicene 61 (Fig. 29).64 Although expecting
the simple bioreduction of 60 to yield 6-aminoquinoline, fluores-
cence and LC-MS analysis revealed that one-electron reduction
by cytochrome P450 reductase in the presence of NADPH under
hypoxia actually resulted in the formation of azoxy-helicene
product 61 giving rise to a 63-fold increase in fluorescence
at 445 nm.
A subsequent report from the same group did report the
enzymatic conversion of 60 to 62 under hypoxic conditions
(Fig. 29); this time using the xanthine/xanthine oxidase enzy-
matic reducing system under hypoxic conditions.65 Wilson and
co-workers investigated a series of quinolone compounds and
reported that 6-nitroquinolone ester 63 (Fig. 29) had a high
anoxic/oxic fluorescence differential (B400–500-fold) and behaved
as a fluorescent probe for cytochrome P450 oxidoreductase and
other NADH dependant reductases under hypoxic conditions.
Fig. 24 Fluorescence images of NTR in living 3-day-old zebrafish.
(A) Zebrafish treated with bioreduced 50, (B) zebrafish treated with 50
(C) zebrafish pre-incubated with dicoumarol inhibitor and subsequently
treated with 50. Scale bar, 500 mm. (Reproduced with permission from
Biosens. Bioelectron., 2015, 63, 112–116. r 2015 Elsevier).
Fig. 25 BODIPY based probes 51–53.
Fig. 26 Confocal fluorescence microscopy images of HeLa cells treated
with 53 (a) HeLa cells under normoxic conditions and (b) HeLa cells under
hypoxic conditions. (Reproduced from Chem. Commun., 2015, 51, 13389–
13392. r 2015 Royal Society of Chemistry).
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Moreover, the in vitro metabolism of 63 showed significant
correlation with that of PR-104A,66 the known dinitrobenza-
mide prodrug, where both were similarly activated in 22
different human tumour cell lines as evidenced using fluores-
cence microscopy and flow cytometry.67
The nitroimidazole–ruthenium conjugate 64 (Fig. 30), one
of the few metal based examples in this review, was reported
by Suzenet, Brindell and co-workers and was found to be
selectively retained in hypoxic over normoxic A549 cells.68
The luminescence properties of 64 were highly sensitive to
the environment where binding to human serum albumin
(HSA) resulted in an emission increase and a lengthening of
the luminescence lifetime (490 ns to 809 ns and 895 ns)
while binding to calf thymus DNA resulted in an emission
decrease of 65% and a shortening of the luminescence lifetime
(660  10 ns to 540  10 ns). Complex 64 was also found to be
highly cytotoxic to cells and thus not applicable as an imaging
agent. A subsequent study by the same authors examined the
biological properties of 64 in detail where the complex was
found to possess higher potency than cisplatin in vitro.69
Recently, Liang, Zhang and co-workers reported 65 (Fig. 30),
a high sensitivity probe for monitoring NTR activity, utilising
both one-photon and two-photon fluorescence.70 65 exhibited a
NTR-induced fluorescence enhancement of ca. 70-fold and a
detection limit of 20 ng mL1. Moreover, 65 was capable of
imaging hypoxic cells with little observed cytotoxicity and high
differentiation between hypoxic and normoxic cells. Imaging of
rat liver tissue slices also exhibited the applicability of 65 to
tissue hypoxia monitoring where it was employed to success-
fully image tissue at imaging depths of 70–160 mm.
Bacterial imaging has also emerged as a potential applica-
tion for bioreductively responsive probes due to the inherent
production of NTR, both type I and type II, by many species of
bacteria.71 Tangney and co-workers at University College Cork
sought to take advantage of NTR enzymes as a non-invasive
reporting strategy for bacterial infection.72 Initial proof of
concept studies utilised the previously described CytoCy5Sr27
in a mouse model where infected mice showed localised fluores-
cence only in organs infected with bacteria. Moreover, mice
Fig. 27 Dual enzyme-responsive sensors 54–56 and coumarin–nitroimidazole conjugates 57 and 58.
Fig. 28 Nitro-substituted benzothiadiazole probe 59.
Fig. 29 6-Nitroquinoline derivatives 60–63.
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bearing subcutaneous tumours that had been colonised with
E. coli also showed selective fluorescence localised within
the tumour while those that were not infected showed a negli-
gible fluorescence signal. A subsequent report from Tangney,
Dubikovskaya and co-workers described a new NTR responsive
bioluminescent probe 66 that was selectively ‘switched on’ by
releasing luciferin 67 in the presence of numerous NTR expres-
sing E. coli strains (Fig. 31).73 66 also successfully demonstrated
high efficiency release of luciferin in an in vivo subcutaneous
xenograft model where a tumour induced by NTR and luciferase
expressing MDA-MB-231 human breast adenocarcinoma cells
exhibited intense bioluminescence when treated with the dye.
Luciferin was also exploited in a recent communication from
Prescher and co-workers where 68 was employed as a ‘caged’
luminophore utilising NTR activity to visualise cell–cell contacts
(Fig. 31).74 The nitroaryl group of 68 prevented luminescence
through electron-withdrawing effects however upon bioreduc-
tion in the presence of NTR, the resulting hydroxylamine was
sufficiently electron rich to give a luciferin analogue that could
be oxidised by luciferase to yield bioluminescence. Moreover,
the authors were able to directly image cell–cell contacts where
cells expressing NTR (activator cells) in direct contact with cells
expressing luciferase (reporter cells) were easily imaged upon
treatment with 68 while those separated by just 1 mm produced
negligible luminescence.
The bioluminescent approach was also recently taken by
Au-Yeung and co-workers where they reported the synthesis of
luciferin derivative 69 (Fig. 31).75 The approach relied on an
aminoluciferin conjugated to a 4-nitrobenzyl carbamate group
which, upon bioreduction in the presence of NTR, yielded
aminoluciferin 70. When treated with NTR in the presence of
NADH and luciferase 69 gave rise to a 100-fold luminescence
enhancement in just 5 minutes. This effect was also applied in
the detection of microbial NTR activity across a range of both
gram positive and gram negative bacteria demonstrating the
potential of 69 as a sensitive, real time probe for the detection
of microbial growth.
Stanforth and co-workers have reported several classes of
nitroaryl–benzothiazole, benzimidazole and benzoxazole deri-
vatives as fluorescent probes to detect NTR activity in clinically
important bacteria (Fig. 32).76,77 Derivatives such as 71 and 72
were shown to function as indicators of NTR activity across a
Fig. 30 Nitroimidazole–ruthenium conjugate 64 and nitrobenzyl conjugate 65.
Fig. 31 NTR responsive bioluminescent probes 66–70.
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range of both gram negative and gram positive bacteria where
strong blue fluorescence was observed upon incubation with
bacteria in culture.
A methylene blue based fluorescent probe 73 has recently been
reported for NTR detection by Jo and co-workers (Fig. 33).78
Through a NTR catalysed 1,6-elimination to yield methylene blue
74, 73was demonstrated as a sensitive and selective probe for NTR
giving rise to ‘turn on’ fluorescence with lmax = 680 nm. 73 was
also investigated as an imaging probe for bacteria where it was
demonstrated to undergo a concentration dependent increase in
fluorescence intensity in response to E. coli growth. Moreover,
singlet oxygen production of 73 was also found to be ‘switched’ in
the presence of NTR demonstrating that 73may also find applica-
tion as an enzyme triggered photodynamic therapy (PDT) agent.
Moerner and co-workers reported the dicyanomethylenedi-
hydrofuran (DCDHF) based fluorophore 75 (Fig. 34) in the
development of enzymatic turnover-activated localisation
microscopy (ETALM); a super-resolution imaging technique
based on single-molecule fluorescence.79 The nitro-aryl com-
pound 75 was shown to be bioreduced in the presence of NTR
to a highly fluorescent red-emitting fluorophore 76 by spectro-
scopic techniques. The NTR reaction was also characterised in
bacterial cells with entire cells displaying ‘turn on fluores-
cence’. Indeed, it was also possible to observe fluorescence on
the single molecule level where incubation of 75 in B. subtilis at
onM levels resulted in fluorescent spots being observed to turn
on and subsequently photobleach on the millisecond timescale
giving detailed information on the localisation of the cytosolic
and membrane bound NTR enzyme.
3. Azo linkages
Aside from the ubiquitous NTRs, both azoreductase (AZR)
enzymes and the NADH:quinone oxidoreductases (also known
as DT-diaphorases) are also known to be expressed at high
levels under hypoxic conditions where they can effect the
reduction of quinones and azo compounds.80 The endogenous
presence of AZR in hepatocellular carcinomas in humans has
also resulted in their exploitation as hypoxia sensitive triggers
in hypoxia activated enzyme therapies.81 In order to investigate
hypoxia-sensitive alternatives to nitroaromatic moieties Nagano
and co-workers developed 77–79 (Fig. 35).82 77–79 consist of an
Fig. 32 Nitroaryl–benzoxazole and benzothiazole derivatives 71 and 72.
Fig. 33 Methylene blue based fluorescent probe 73 and the reduction
product 74.
Fig. 34 Dicyanomethylenedihydrofuran based fluorophores 75 and 76.
Fig. 35 Black Hole Quencher–dicarbocyanine conjugates 77–79.
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azo based Black Hole Quencherr (BHQ) dye coupled with a near
infrared (NIR) dicarbocyanine fluorophore. Due to the presence of
Fo¨rster resonance energy transfer (FRET) between BHQ and the
fluorophore, 77–79 exhibited extremely weak fluorescence (Fig. 36).
However, a large fluorescence increase (50–100 fold) was triggered
by the cleavage of the azo bond after enzymatic reactions using rat
liver microsomes under hypoxic conditions. The ability of 77 to
detect hypoxia was also demonstrated by the treatment of MCF-7
cells where the probe showed strong fluorescence only in cells
incubated under hypoxic conditions. Moreover, 77 could also
detect hypoxia in vivo using an ischemia model of the mouse liver
where it was readily reduced in an ischemic liver while remaining
non fluorescent in a normoxic liver.
A subsequent publication from Hanaoka, Nagano and
co-workers reported a similar strategy in which two rhodamine
based azo dyes, 80 and 81 were shown to be non-fluorescent in
aqueous solution (Fig. 37).83 The quenching involved was
thought to be due to conformational rotation around
the NQN bond resulting in an ultrafast radiationless decay
profile of the excited state. Subsequent reductive cleavage of the
azo bond, however, restored fluorescence by regenerating the
original fluorophores 2Me rhodamine green (2Me RG) (lmax =
520 nm) or 2Me Si-rhodamine 600 (2Me SiR 600) (lmax =
613 nm) for 80 and 81 respectively.84 The in vitro detection of
hypoxia using rat liver microsomes, which contain various
oxygen sensitive reductases, revealed a rapid increase in the
fluorescence intensity of both 80 and 81 by 630-fold or 20-fold,
respectively. Similarly, a time-dependent increase in emission,
measured by both confocal fluorescence microscopy and flow-
cytometric analysis, was observed in A549 cells treated with 80
and 81 under varying degrees of hypoxia where negligible
emission was measured inside cells cultured under normoxic
conditions. Perhaps most interestingly 80 was observed to func-
tion as a fluorescent probe capable of visualising retinal hypoxia
in a rat model. Fluorescence imaging of a branch retinal artery
occlusion (BRAO) treated with 80 resulted in emission intensity
in the area of retinal hypoxia being considerably higher than that
observed in a normoxic area (389.8%  189.8% vs. 100.0% 
17.2% (mean  SD)) (Fig. 37).
Qian et al. also took advantage of the azo linkage in the
development of hypoxia probe 82 (Fig. 38).85 82 was designed
to take advantage of the FRET pair of rhodamine B and azo-
naphthalimide where reduction of the azo bond resulted in a
Fig. 36 The design strategy of the family of FRET based quencher
fluorophores 77–79. (Reproduced with permission from J. Am. Chem.
Soc., 2010, 132, 15846–15848. r 2010 American Chemical Society).
Fig. 37 Chemical structures of probes 80 and 81. Fluorescence imaging of branch retinal artery occlusion (BRAO) in a rat model with 80. (a) Hypoxia
imaging method after BRAO. (b and c) Fluorescence imaging of the isolated retina two hours after treatment with a low (b)- or high (c)-magnification
lens. Scale bars: 1 mm (b) and 100 mm (c). The arrow in (b) indicates the point of laser irradiation. (d) Comparison of the fluorescence intensities observed
in hypoxic and normoxic areas. (Reproduced with permission from Angew. Chem., Int. Ed., 2013, 52, 13028–13032. r 2013 John Wiley and Sons).
Fig. 38 Azo-naphthalimide–rhodamine B conjugate 82.
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disruption of FRET and led to an enhancement of fluorescence
at 581 nm. The reduction of 82 was effected by cytochrome
P450 reductase and imaging in both normoxic and hypoxic
HeLa cells demonstrated it’s potential applicability as a sensi-
tive biological imaging agent for hypoxia where there was a
9 fold variation in the ratio of fluorescence intensity between
hypoxic and normoxic cells.
Romieu and co-workers developed the rhodamine based
probe 83 and its water soluble analogue 84 for the selective
detection of AZR in bacterial cultures (Fig. 39).86 83 was shown
to exhibit a ‘turn on’ fluorescence response to mimicked AZR
conditions using the biocompatible reducing agent sodium
dithionate which resulted in a 250-fold increase in fluorescence
at 520 nm (Fig. 40). A post-synthetic derivatisation approach
allowed the assembly of 84 utilising copper-catalysed Huisgen
1,3-dipolar cycloaddition where the resultant positively charged
tetralkylammonium groups, inferred both cell permeability
and water solubility to the dye. In vitro activation of 84 was
also demonstrated in a number of different bacterial strains
(E. coli, P. aeruginosa, S. aureus and E. faecalis) where time-
course experiments revealed a significant increase in in cellulo
fluorescence of 84 in less than 3 hours. The fluorescent
response of 83 was considerably lower, thought to be as a result
its poor aqueous solubility.
Jayagopal and co-workers also utilised a FRET based strategy
in the design of 85 a ‘turn on’ probe sensitive to AZR which is
known to contribute to reductive stress in retinopathy (Fig. 41).87
85 displayed a 6.6 fold fluorescence increase when incubated in
retinal neuronal cells (R28) and human retinal pigment epithelial
cells (ARPE-19) for 4 h under hypoxic conditions. Additionally, 85
was demonstrated to successfully image focal hypoxia within laser-
induced choroidal neovascularisation (LNCV) lesions (a mouse
model for neovascular diseases such as macular degeneration) but
not in adjacent healthy vascularised retinal tissue.
An original approach was taken by Bichenkova, Freeman and
co-workers who published two reports on a pair of strained tetra-
axial fluorescent probes for AZR activity 86 and 87 (Fig. 42).88,89
The authors proposed that cleavage of the azo functionality
prevented a dansyl (in the case of 86) or a pyrene (in the case
or 87) moiety from forming a dimer complex. Using mole-
cular dynamics simulations the authors suggested that upon
reduction of the azo group a ring flip of the cyclohexane ring
from a tetra-axial to a tetra-equatorial conformation occurred
resulted in a change from dimer (555 nm) to blue-shifted
monomer emission (448 nm) (Fig. 43(a)). Moreover, when
C. perfringens were treated with 86 for 12 hours the resulting
Fig. 39 Rhodamine based probe 83 and its water soluble analogue 84.
Fig. 40 Fluorescence emission spectra 83 in phosphate buffered saline +
1% DMSO before and after addition of sodium dithionite (100 equiv.). Inset:
Images of the corresponding solutions under UV illumination conditions.
(Reproduced from Chem. Commun., 2013, 49, 8815–8817. r 2013 Royal
Society of Chemistry).
Fig. 41 FRET based probe 85.
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supernatant exhibited an 89% dimer emission decrease with a
concomitant 89% increase in monomer fluorescence clearly
demonstrating the applicability of 86 as an enzymatic biomarker
for bacteria (Fig. 43(b)).
Sun, Li and co-workers recently took advantage of the azo
linkage in the preparation of a family of iridium(III) complexes
as phosphorescent probes for hypoxia.90 The azo-based probes
were found to be non-emissive in solution but upon treatment
with rat liver microsomes under hypoxic conditions the phos-
phorescence intensity of each complex increased sharply with
the fluorescence of 88 being particularly effective increasing by
58 fold. In vitro hypoxia experiments were conducted in 3D multi-
cellular spheroids in order to mimic the hypoxic microenviron-
ment of cancerous tumours.91 Negligible phosphorescence was
observed from each probe in small spheroids (150 mm in diameter)
while large spheroids (500 mm in diameter) displayed bright
phosphorescence in the hypoxic central region (Fig. 44).
4. Other functionalities
Quinones in general have the potential to undergo one-electron
reduction by cytochrome P450 reductase which are available in
high levels in hypoxic environments.81 Tanabe and co-workers
Fig. 42 Strained tetra-axial fluorescent probes for AZR activity 86 and 87.
Fig. 44 Confocal images of 3D multicellular spheroids incubated with 88. (a) Small 3D spheroids (b) large 3D spheroids (c) merged images of Z-stack
images of an intact spheroid showing 3D biodistribution of 88 throughout. (Reproduced from Sci. Rep., 2015, 5, 14837. Shared under the Creative
Commons Attribution 4.0 International License).
Fig. 43 (a) Reduction of the azo group in 86 results in a ring flip of the cyclohexane moiety to the more stable tetra-equatorial conformation. (b) Fluorescent
changes associated with the bioreduction of 86 in the presence of C. perfringens cell culture supernatants known to contain azoreductive enzymes over 12 hours.
(Reproduced from (a) Chem. Commun., 2013, 49, 8815–8817, (b) Chem. Commun., 2012, 48, 6393.r 2013 and 2012 Royal Society of Chemistry).
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have reported a number of hypoxia sensitive molecules taking
advantage of both reduction responsive fluorescent imaging
agents and phosphorescent metal complexes.92,93 Their first
contribution in 2008 described a hypoxia-specific fluorescence
probe 89 based on an indolequinone unit conjugated to two
coumarin fluorophores (Fig. 45).94 89 showed weak fluores-
cence, attributed to the coumarin units being efficiently
quenched by the indolequinone via a photoinduced electron
transfer (PET) process. Ab initio calculations and laser flash
photolysis both supported this theory where the results demon-
strated that the photolysis of 89 induced electron transfer from
the excited coumarin units to the indolequinone. One-electron
reduction of 89 in the presence of NADPH and cytochrome P450
reductase under hypoxic conditions led to efficient decomposi-
tion and release of 2 molecules of coumarin-3-carboxylic acid.
Similarly, lysate of the human fibrosarcoma cell line HT-1080
resulted in the same decomposition and in both cases led to
intense fluorescence emission at 420 nm, four times as strong
as that of the sample incubated under normoxic conditions.
A subsequent report described the synthesis of 90 a rhodol–
indolequinone conjugate that displayed weak fluorescence
before bioreduction in the presence of cytochrome P450 reduc-
tase and NADPH released the rhodol fluorophore with intense
fluorescence at 550 nm (Fig. 45).95 Intracellular rhodol release
was also revealed by in vitro fluorescence imaging of A549 cells
under hypoxic conditions.
Both cytochrome P450 reductases and other haemoproteins
have also been implicated in the reduction of the N-oxide
functionality.96 Although less explored in the context of fluores-
cence imaging a series of naphthalimide N-oxides (91–95)
(Fig. 46) were reported by Qian and co-workers where their
ability to bind to DNA as well as their potential as fluorescent
Fig. 45 Indolequinone conjugates 89 and 90.
Fig. 46 Naphthalimide N-oxide derivatives 91–95.
Fig. 47 Malachite green derivatives 96 and 97.
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markers for hypoxia was evaluated.97 Fluorescence image ana-
lysis indicated that 91 was particularly effective as a hypoxia
marker where it displayed a hypoxic/normoxic fluorescence
differential of 17 times when incubated for 4.5 h in V79 Chinese
hamster cells. The authors suggested that this marked fluores-
cence increase was likely to be a result of a bis-bioreduction
process where the N-oxide was reduced to the corresponding
tertiary amine while the nitro group was also subsequently
reduced to the corresponding primary amine.
Using an alternative approach Hanaoka, Nagano and
co-workers have reported, to the best of my knowledge, the
only example of a non-metal based reversible probe for hypoxia,
96 (Fig. 47).98 The design of 96 was based on a FRET mecha-
nism where a malachite green derivative 97 acted as a FRET
acceptor and the NIR dicarbocyanine fluorophore Cy5 as a
FRET donor. 96 showed very weak emission under normoxic
conditions, however, upon bioreduction and formation of a
carbon centred radical, emission at 670 nm was ‘switched on’.
Electron spin resonance (ESR) spectroscopy confirmed the
existence of a carbon centred radical under hypoxia with no
signal being observed under normoxic conditions. The authors
also demonstrated successful detection of repeated cycles of
hypoxia–normoxia in live A549 human breast cancer cells where
the fluorescence intensity rapidly decreased upon exposure of
the cells to air (Fig. 48).
5. Conclusions
This Feature Article has demonstrated the diversity of fluores-
cent sensors and probes that have been developed for the
detection not only of tumour hypoxia but also for reductase
enzymes found in various genera of bacteria. The examples
presented emphasise the versatility of this strategy where a
wide range of structurally varied dyes have been utilised and
have been applied both in vitro and in vivo for hypoxia detection
and bacterial monitoring. Although significant progress has
been made to date, further investigation is needed to exploit
the full sensing potential of bioreductase enzymes and to
understand the complex role played by them in hypoxic cells.
In particular the development of reversible hypoxia probes,
of which there are not many examples, will be an important
consideration as the field moves in to the future. Within this
context it is clear that fluorescent sensors like those described
provide massive potential across a range of applications from
medical diagnostics to environmental monitoring and beyond.
Promisingly, with the many recent reports of hypoxia activated
fluorescent agents it is obvious this is a rapidly expanding area
gaining interest from research groups around the world. With
significant research effort I envisage that the development of
fluorescent probes for the detection of hypoxia will be recog-
nised as an important field of research moving in to the future
and continued investigation will lead to more diverse methods
for hypoxia detection and tumour imaging.
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